Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL4451270 | 0.94 | MAPT (0.31) | MAPTLMNAMETAP2METAP1HDAC6 | |
| SCHEMBL14690221 | 0.93 | MAPT (0.32) | MAPTLMNAMETAP2METAP1HDAC6 | |
| SCHEMBL8844752 | 0.90 | MAPT (0.33) | MAPTLMNAMETAP2METAP1HDAC6 | |
| SCHEMBL18145367 | 0.89 | ELANE (0.37) | MAPTLMNA | |
| SCHEMBL4974616 | 0.89 | — | — | |
| SCHEMBL44290 | 0.88 | LMNA (0.35) | MAPTLMNAMETAP2METAP1HDAC6 | |
| SCHEMBL5526503 | 0.88 | ELANE (0.32) | — | |
| SCHEMBL2534586 | 0.87 | MEN1 (0.38) | MAPTLMNAMETAP2METAP1HDAC6 | |
| SCHEMBL7707716 | 0.87 | SLC22A6 (0.44) | MAPTLMNAKDM4EPOLBHPGD | |
| SCHEMBL2849876 | 0.87 | KDM4E (0.37) | MAPTLMNAKDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112839979-B | Method for preparing releasable polymeric reagents | 尼克塔治疗公司 | 2024-06-21 | — | — | CN | claimed |
| US-11952461-B2 | Siloxy polyethylene glycol and derivatives thereof | SUNBIO, INC. (KR) | 2024-04-09 | — | — | US | claimed |
| US-11932726-B2 | Method of making releasable polymeric reagents | NEKTAR THERAPEUTICS (US) | 2024-03-19 | — | — | US | claimed |
| US-20220298302-A1 | SILOXY POLYETHYLENE GLYCOL AND DERIVATIVES THEREOF | SUNBIO, INC. (KR) | 2022-09-22 | — | — | US | claimed |
| CN-107708675-B | Compositions and kits for pseudoplastic microgel matrices | 罗查尔科技有限责任公司 | 2022-07-22 | — | — | CN | claimed |
| US-20210388161-A1 | METHOD OF MAKING RELEASABLE POLYMERIC REAGENTS | NEKTAR THERAPEUTICS | 2021-12-16 | — | — | US | claimed |
| EP-3864068-A2 | METHOD OF MAKING RELEASABLE POLYMERIC REAGENTS | Nektar Therapeutics (US) | 2021-08-18 | — | — | EP | claimed |
| CN-112839979-A | Method for preparing releasable polymeric reagents | 尼克塔治疗公司 | 2021-05-25 | — | — | CN | claimed |
| US-20200246471-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | NEKTAR THERAPEUTICS (US) | 2020-08-06 | — | — | US | claimed |
| US-20110238000-A1 | POLYMER-CONJUGATED ALBUMIN HYDROGELS FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2011-09-29 | — | — | US | claimed |
| JP-2005538224-A | — | — | 2005-12-15 | — | — | JP | claimed |
| EP-1546235-A2 | WATER-SOLUBLE POLYMER ALKANALS | Nektar Therapeutics Al, Corporation (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050009988-A1 | Polymer derivatives having particular atom arrangements | NEKTAR THERAPEUTICS | 2005-01-13 | — | — | US | claimed |
| WO-2005000360-A2 | PEG DERIVATIVES HAVING AN AMIDOCARBONATE LINKAGE | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2005-01-06 | — | — | WO | claimed |
| US-20040116649-A1 | Polyoxyethylene glycol; purity, storage stability | NEKTAR THERAPEUTICS | 2004-06-17 | — | — | US | claimed |
| WO-2004022630-A2 | WATER-SOLUBLE POLYMER ALKANALS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2004-03-18 | — | — | WO | claimed |
| US-20030129500-A1 | Organic carbonate additives for nonaqueous electrolyte rechargeable electrochemical cells | GREATBATCH, INC. | 2003-07-10 | — | — | US | claimed |
| EP-1086118-A4 | VITAMIN B 12? DERIVATIVES AND METHODS FOR THEIR PREPARATION | BIOTECH AUSTRALIA PTY LTD (AU) | 2002-05-02 | — | — | EP | claimed |
| EP-1086118-A1 | VITAMIN B 12? DERIVATIVES AND METHODS FOR THEIR PREPARATION | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 2001-03-28 | — | — | EP | claimed |
| WO-1999065930-A1 | VITAMIN B12 DERIVATIVES AND METHODS FOR THEIR PREPARATION | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1999-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009988-A1 | Polymer derivatives having particular atom arrangements | CD44, PIGO, PGLS | MAPT 267/4885LMNA 2516/4885METAP2 3422/4885 |
| US-11932726-B2 | Method of making releasable polymeric reagents | FGB, PCBP1, PFAS | MAPT 2710/4885LMNA 1516/4885METAP2 2244/4885 |
| US-20200246471-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | CD44, PIGO, PGLS | MAPT 267/4885LMNA 2516/4885METAP2 3422/4885 |
| US-20210388161-A1 | METHOD OF MAKING RELEASABLE POLYMERIC REAGENTS | FGB, PCBP1, PFAS | MAPT 2710/4885LMNA 1516/4885METAP2 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.